Who makes intravenous graniseton?

intravenous graniseton is developed by Mohamed Youssef Mohamed.

What development phase is intravenous graniseton in?

intravenous graniseton is in Phase 1.

Last reviewed 2026-04-19 · How we verify

intravenous graniseton

Mohamed Youssef Mohamed · Phase 1 active Small molecule

At a glance

Generic name	intravenous graniseton
Also known as	IV Grantryl
Sponsor	Mohamed Youssef Mohamed
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison Between IT Fentanyl and IV Granisetron in Prevention of Vomiting in CS Under Spinal Anesthesia (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

intravenous graniseton CI brief — competitive landscape report
intravenous graniseton updates RSS · CI watch RSS
Mohamed Youssef Mohamed portfolio CI